文献速递糖尿病

ABCC8基因突变所致高胰岛素性低血糖症中硝苯地平治疗的评估

Assessment of Nifedipine Therapy in Hyperinsulinemic Hypoglycemia due to Mutations in the ABCC8 Gene.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

该研究对11例因ABCC8基因突变导致高胰岛素性低血糖症(HH)且对二氮嗪无反应的住院患儿进行硝苯地平剂量递增治疗,最大剂量至2.5 mg/kg/d。在最大剂量治疗中位6.5天后,无一例患者血糖控制改善或低血糖发作减少。结论认为ABCC8基因突变所致HH对硝苯地平治疗无反应。

要点

  • 11例ABCC8突变致HH且对二氮嗪无反应的患儿接受硝苯地平剂量递增治疗。
  • 硝苯地平最大剂量2.5 mg/kg/d,中位治疗6.5天后无患者血糖控制改善。
  • ABCC8基因突变所致HH对硝苯地平治疗无反应。

核心结论

  • ABCC8基因突变所致的高胰岛素性低血糖症对硝苯地平治疗无反应。
  • KATP通道基因突变可能使L型钙通道对硝苯地平治疗无效。

研究设计与样本

  • 硝苯地平剂量递增治疗研究。
  • 纳入11例因ABCC8基因突变导致高胰岛素性低血糖症且对二氮嗪无反应的住院患儿,来自三级医院。

主要发现

  • 患者中位年龄0.44岁(范围0.14至3.77)。
  • ABCC8基因突变:纯合3例,父源杂合4例,复合杂合4例。
  • 18F-DOPA PET/CT显示2例为局灶性病变,其余为弥漫性HH。
  • 1例单用硝苯地平,其余联合奥曲肽/胰高血糖素/二氮嗪或玉米淀粉。
  • 在最大剂量2.5 mg/kg/d治疗中位6.5天(范围3至23天)后,无一例患者血糖控制改善,低血糖发作持续。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Previous case reports have documented the effectiveness of l-type calcium channel blockers (such as nifedipine and verapamil) for treating different forms of hyperinsulinemic hypoglycemia (HH). OBJECTIVE: To systematically assess the glycemic response to nifedipine therapy in 11 patients with HH due to mutations in the ABCC8 gene. DESIGN: Dose escalation of nifedipine therapy. SETTINGS AND PATIENTS: Eleven children who were inpatients at a tertiary hospital and had diazoxide unresponsive HH due to mutations in the ABCC8 gene. INTERVENTION(S): Nifedipine was administered orally at an escalating dose up to a maximum of 2.5 mg/kg/d. MAIN OUTCOME MEASURES: Improvement in glycemic control, avoidance of hypoglycemic episodes, reduction of intravenous glucose infusion, and reduction in the requirements of other medical therapies. RESULTS: The median age of the patients was 0.44 years (range 0.14 to 3.77). The ABCC8 gene mutations were homozygous in 3 cases, paternally inherited heterozygous in 4, and compound heterozygous in 4. 18F-DOPA PET/CT scan demonstrated a focal lesion in 2 cases and the rest were diffuse HH disease. One subject had nifedipine as monotherapy, whereas the rest had it in combination with octreotide/glucagon/diazoxide or cornstarch. After a median of 6.5 (3 to 23) days of maximal (2.5 mg/kg/d) dose of nifedipine therapy, none of the patients showed any improvement in glycemic control and patients continued to have hypoglycemic episodes. CONCLUSIONS: HH due to mutations in the ABCC8 gene does not respond to nifedipine therapy. Mutations in the KATP channel genes might render the l-type calcium channel ineffective to therapy with nifedipine.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Güemes M, Shah P, Silvera S, et al. Assessment of Nifedipine Therapy in Hyperinsulinemic Hypoglycemia due to Mutations in the ABCC8 Gene. J Clin Endocrinol Metab. 2017. PMID: 27898257. doi:10.1210/jc.2016-2916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。